Dr. John M. Dye Jr., Viral Immunology branch chief, works in the laboratory at the U.S. Army Medical Research Institute of Infectious Diseases in Frederick, Maryland. Dye is leading a team that is conducting a study with nonhuman primates involving the experimental drug ZMapp, an experimental treatment for Ebola patients. USAMRIID scientists here have worked for years on earlier versions of the Mapp Biopharmaceuticals cocktail of three different monoclonal antibodies. The drug is in Phase 1 clinical trials, but has not yet has completed testing in people for safety or effectiveness. USAMRIID photo Dr. John M. Dye Jr., Viral Immunology branch chief, works in the laboratory at the U.S. Army Medical Research Institute of Infectious Diseases in Frederick, Maryland. Dye is leading a team that is conducting a study with nonhuman primates involving the experimental drug ZMapp, an experimental treatment for Ebola patients. USAMRIID scientists here have worked for years on earlier versions of the Mapp Biopharmaceuticals cocktail of three different monoclonal antibodies. The drug is in Phase 1 clinical trials, but has not yet has completed testing in people for safety or effectiveness. USAMRIID photo SHARE: Download: Full Size (0.54 MB) Credit: VIRIN: 126650-T-WVA24-906.jpg Photo Gallery